SPOKANE, WA, September 9, 2026 (EZ Newswire) -- Dr. Wm. Philip Werschler, a board-certified dermatologist and veteran clinical trial investigator, has surpassed 3,000 career research citations and 75,000 reads of his published work on ResearchGate, the global network for scientists and researchers. The milestone reflects a body of more than 140 publications spanning dermatology, aesthetic medicine and clinical drug development.
ResearchGate's comparative analytics place Werschler above 94% of dermatology researchers on the platform by publication and citation volume.
A Research Record Spanning the Modern Era of Aesthetic Medicine
Much of Werschler's published work is indexed in PubMed as part of the U.S. National Library of Medicine, and appears in journals including the Journal of the American Academy of Dermatology, Dermatologic Surgery, JAMA Dermatology, Aesthetic Surgery Journal, Plastic and Reconstructive Surgery and the Journal of Clinical and Aesthetic Dermatology.
His research spans a broad range of medical and aesthetic dermatology, including:
- Aesthetic and procedural dermatology: Neuromodulators, dermal fillers, lasers and other energy-based devices
- Inflammatory and immune-mediated disease: Acne, rosacea, psoriasis and psoriatic arthritis, atopic dermatitis (eczema), urticaria, hidradenitis suppurativa
- Infectious disease of the skin: Viral skin infections including warts, molluscum and herpes
- Hair and scalp disorders: Alopecia
- Growths, precancers and skin cancer: Seborrheic keratoses, actinic keratoses, nonmelanoma skin cancer
Taken together, that record traces much of the arc of modern medical and aesthetic dermatology.
Citations accumulate when other scientists reference a researcher's work in their own studies, which makes citation counts a widely used measure of how much a body of research has informed the broader field. Reads reflect how often colleagues view a publication summary, click a figure, or view or download the full text.
“Numbers like these are really a proxy for something simpler, which is whether the work has been useful to other clinicians,” said Werschler. “Citations mean colleagues are building on the research and using it to make decisions for patients. That is the part that matters to me.”
From Foundational Trials to Today’s Standards of Care
Werschler has served as a principal investigator on clinical research across dermatology and aesthetic medicine, including pivotal clinical trials for Botox Cosmetic, which received FDA approval for aesthetic use in 2002. He founded Premier Clinical Research and BreakAway Research and has held editorial roles at major dermatology journals, including as founding aesthetic Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology.
“I have been fortunate to be involved in clinical research since the early days of modern aesthetic medicine,” said Werschler. “Staying close to the evidence is what keeps a physician sharp, and it is ultimately what serves patients best.”
About Dr. Philip Werschler
Dr. Wm. Philip Werschler, MD, is a Clinical Professor of Medicine and Dermatology at the Elson S. Floyd College of Medicine at Washington State University. Board-certified in dermatology, he practices as a dermatologist, cosmetic surgeon and clinical investigator in Spokane, Washington. He founded Premier Clinical Research and BreakAway Research and has served as a clinical trial investigator across dermatology and aesthetic medicine, including the pivotal clinical trials for Botox Cosmetic, which received FDA approval for aesthetic use in 2002. He has served as Editor-in-Chief of Cosmetic Dermatology and as founding aesthetic editor of the Journal of Clinical and Aesthetic Dermatology, and he is a fellow of the American Academy of Dermatology, the American Society for Dermatologic Surgery and the American Academy of Cosmetic Surgery. More information is available at spokanederm.com.
Media Contact
content@thebestreputation.com
+1 866-322-8316
###
SOURCE: Spokane Dermatology Clinic
For questions regarding this release or its content, contact hello@eznewswire.com for immediate assistance.